Disseminated Intravascular Coagulation in Hematologic Malignancies

 

 Buy Article Permissions and Reprints

ABSTRACT

Disseminated intravascular coagulation (DIC) significantly contributes to the bleeding and thrombotic complications in patients with hematologic malignancies. As shown in other cancer settings, an underlying condition of activation of the coagulation system leading to a prothrombotic state of chronic or subclinical DIC is detectable. A variety of disease- or treatment-related factors may affect this condition, enhancing the risk of thrombosis or of bleeding and further triggering mechanisms of DIC in this setting. An overt DIC is diagnosed in ~15% of patients with acute leukemia, and bleeding manifestations prevail over thrombosis, with the highest and most harmful clinical impact in acute promyelocytic leukemia (APL). Pathogenic mechanisms include a series of intrinsic properties of malignant cells, able to directly activate the coagulation system or to stimulate prothrombotic effects by the host cells. Moreover, chemotherapy or concomitant infections play an important concurrent role. In this review the coagulation abnormalities, clinical manifestations, and the presently known pathophysiologic mechanisms of DIC in patients with hematologic malignancies are discussed, focusing on the most extensively studied condition of APL. Current approaches and open issues for the management and treatment of these patients are also reviewed.

REFERENCES

• 1 Risak E. Die Fibrinopenie.  Z Klin Med. 1935;  128 605-609
  PubMedGoogle Scholar
• 2 Croizat P, Favre-Gilly J. Les aspects du syndrome hémorragique des leucémies.  Sang. 1949;  20 417-421
  PubMedGoogle Scholar
• 3 Hillestad L K. Acute promyelocytic leukemia.  Acta Med Scand. 1957;  159(3) 189-194
  CrossrefPubMedGoogle Scholar
• 4 Rand J J, Moloney W D, Sise H S. Coagulation defects in acute promyelocytic leukemia.  Arch Intern Med. 1969;  123(1) 39-47
  CrossrefPubMedGoogle Scholar
• 5 Gralnick H R, Marchesi S, Givelber H. Intravascular coagulation in acute leukemia: clinical and subclinical abnormalities.  Blood. 1972;  40(5) 709-718
  PubMedGoogle Scholar
• 6 Al-Mondhiry H. Hypofibrinogenemia associated with vincristine and prednisone therapy in lymphoblastic leukemia.  Cancer. 1975;  35(1) 144-147
  CrossrefPubMedGoogle Scholar
• 7 Champion L A, Luddy R E, Schwartz A D. Disseminated intravascular coagulation in childhood acute lymphocytic leukemia with poor prognostic features.  Cancer. 1978;  41(4) 1642-1646
  CrossrefPubMedGoogle Scholar
• 8 Daly P, Brito-Babapulle V, Lawlor E, Blaney C, Parreira A, Catovsky D. Variant translocation t(8;22) and abnormalities of chromosome 15(q22) and 17(q12-21) in a Burkitt's lymphoma/leukaemia with disseminated intravascular coagulation.  Br J Haematol. 1986;  64(3) 561-569
  CrossrefPubMedGoogle Scholar
• 9 Ribeiro R C, Pui C H. The clinical and biological correlates of coagulopathy in children with acute leukemia.  J Clin Oncol. 1986;  4(8) 1212-1218
  PubMedGoogle Scholar
• 10 Sarris A, Cortes J, Kantarjian H et al.. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.  Leuk Lymphoma. 1996;  21(1-2) 85-92
  CrossrefPubMedGoogle Scholar
• 11 Green D. Management of bleeding complications of hematologic malignancies.  Semin Thromb Hemost. 2007;  33(4) 427-434
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Levi M. Disseminated intravascular coagulation in cancer patients.  Best Pract Res Clin Haematol. 2009;  22(1) 129-136
  CrossrefPubMedGoogle Scholar
• 13 Tallman M S, Abutalib S A, Altman J K. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia.  Semin Thromb Hemost. 2007;  33(4) 330-338
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia.  Semin Thromb Hemost. 2001;  27(6) 593-604
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Gugliotta L, Mazzucconi M G, Leone G et al.. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.  Eur J Haematol. 1992;  49 63-66
  CrossrefPubMedGoogle Scholar
• 16 Ottinger H, Belka C, Kozole G et al.. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance.  Eur J Haematol. 1995;  54(3) 186-194
  CrossrefPubMedGoogle Scholar
• 17 Zangari M, Anaissie E, Barlogie B et al.. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.  Blood. 2001;  98(5) 1614-1615
  CrossrefPubMedGoogle Scholar
• 18 Dally N, Hoffman R, Haddad N, Sarig G, Rowe J M, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia—a single center experience in 34 patients.  Thromb Res. 2005;  116(2) 109-114
  CrossrefPubMedGoogle Scholar
• 19 De Stefano V, Sorà F, Rossi E et al.. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.  J Thromb Haemost. 2005;  3(9) 1985-1992
  CrossrefPubMedGoogle Scholar
• 20 Falanga A, Barbui T, Rickles F R, Levine M N. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis.  Thromb Haemost. 1993;  70 540-542
  PubMedGoogle Scholar
• 21 Falanga A, Ofosu F A, Delaini F et al.. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions.  Blood Coagul Fibrinolysis. 1994;  5(5 suppl 1) S19-S23 discussion 59-64
  PubMedGoogle Scholar
• 22 Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient.  Semin Thromb Hemost. 1999;  25(2) 173-182
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Chong B H, Lee S-H. Management of thromboembolism in hematologic malignancies.  Semin Thromb Hemost. 2007;  33(4) 435-448
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Arbuthnot C, Wilde J T. Haemostatic problems in acute promyelocytic leukaemia.  Blood Rev. 2006;  20(6) 289-297
  CrossrefPubMedGoogle Scholar
• 25 Stein E, McMahon B, Kwaan H, Altman J K, Frankfurt O, Tallman M S. The coagulopathy of acute promyelocytic leukaemia revisited.  Best Pract Res Clin Haematol. 2009;  22(1) 153-163
  CrossrefPubMedGoogle Scholar
• 26 Nur S, Anwar M, Saleem M, Ahmad P A. Disseminated intravascular coagulation in acute leukaemias at first diagnosis.  Eur J Haematol. 1995;  55(2) 78-82
  CrossrefPubMedGoogle Scholar
• 27 Higuchi T, Toyama D, Hirota Y et al.. Disseminated intravascular coagulation complicating acute lymphoblastic leukemia: a study of childhood and adult cases.  Leuk Lymphoma. 2005;  46(8) 1169-1176
  CrossrefPubMedGoogle Scholar
• 28 Dixit A, Chatterjee T, Mishra P et al.. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.  Clin Appl Thromb Hemost. 2007;  13(3) 292-298
  CrossrefPubMedGoogle Scholar
• 29 Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma.  Cancer. 2003;  98(6) 1239-1242
  CrossrefPubMedGoogle Scholar
• 30 Sase T, Wada H, Yamaguchi M et al.. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma.  Thromb Haemost. 2005;  93(1) 153-159
  PubMedGoogle Scholar
• 31 Wada H, Sase T, Yamaguchi M. Hypercoagulant states in malignant lymphoma.  Exp Oncol. 2005;  27(3) 179-185
  PubMedGoogle Scholar
• 32 Avvisati G, ten Cate J W, Sturk A, Lamping R, Petti M G, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia.  Br J Haematol. 1988;  70(1) 43-48
  CrossrefPubMedGoogle Scholar
• 33 Cordonnier C, Vernant J P, Brun B et al.. Acute promyelocytic leukemia in 57 previously untreated patients.  Cancer. 1985;  55(1) 18-25
  CrossrefPubMedGoogle Scholar
• 34 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients.  Blood. 1990;  75(11) 2112-2117
  PubMedGoogle Scholar
• 35 Sanz M A, Martín G, González M et al.. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.  Blood. 2004;  103(4) 1237-1243
  CrossrefPubMedGoogle Scholar
• 36 Tallman M S, Lefèbvre P, Baine R M et al.. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.  J Thromb Haemost. 2004;  2(8) 1341-1350
  CrossrefPubMedGoogle Scholar
• 37 Di Bona E, Avvisati G, Castaman G et al.. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.  Br J Haematol. 2000;  108(4) 689-695
  CrossrefPubMedGoogle Scholar
• 38 Kim H, Lee J-H, Choi S-J, Kim W K, Lee J S, Lee K H. Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients.  Haematologica. 2004;  89(5) 622-624
  PubMedGoogle Scholar
• 39 Raanani P, Segal E, Levi I et al.. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA—a manifestation of the basic disease or the treatment.  Leuk Lymphoma. 2000;  37(5–6) 605-610
  CrossrefPubMedGoogle Scholar
• 40 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.  Blood. 1998;  91(9) 3093-3102
  PubMedGoogle Scholar
• 41 Rovelli A, Biondi A, Cantù Rajnoldi A et al.. Microgranular variant of acute promyelocytic leukemia in children.  J Clin Oncol. 1992;  10(9) 1413-1418
  PubMedGoogle Scholar
• 42 Bauer K A, Rosenberg R D. Thrombin generation in acute promyelocytic leukemia.  Blood. 1984;  64(4) 791-796
  CrossrefPubMedGoogle Scholar
• 43 Noguera N I, Breccia M, Divona M et al.. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.  Leukemia. 2002;  16(11) 2185-2189
  CrossrefPubMedGoogle Scholar
• 44 Kiyoi H, Naoe T, Yokota S Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho) et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia.  Leukemia. 1997;  11(9) 1447-1452
  CrossrefPubMedGoogle Scholar
• 45 Rodeghiero F, Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia.  Leukemia. 1994;  8(suppl 2) S20-S26
  PubMedGoogle Scholar
• 46 Watanabe R, Murata M, Takayama N Keio Hematology-Oncology Cooperative Study Group (KHOCS) et al. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia.  Thromb Haemost. 1997;  77(4) 641-645
  Article in Thieme ConnectPubMedGoogle Scholar
• 47 Falanga A, Consonni R, Marchetti M et al.. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells.  Blood. 1998;  92(1) 143-151
  PubMedGoogle Scholar
• 48 Wang J, Weiss I, Svoboda K, Kwaan H C. Thrombogenic role of cells undergoing apoptosis.  Br J Haematol. 2001;  115(2) 382-391
  CrossrefPubMedGoogle Scholar
• 49 Gordon S G, Franks J J, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue.  Thromb Res. 1975;  6(2) 127-137
  CrossrefPubMedGoogle Scholar
• 50 Falanga A, Alessio M G, Donati M B, Barbui T. A new procoagulant in acute leukemia.  Blood. 1988;  71(4) 870-875
  PubMedGoogle Scholar
• 51 Alessio M G, Falanga A, Consonni R et al.. Cancer procoagulant in acute lymphoblastic leukemia.  Eur J Haematol. 1990;  45(2) 78-81
  CrossrefPubMedGoogle Scholar
• 52 Falanga A, Consonni R, Marchetti M et al.. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid.  Leukemia. 1994;  8(1) 156-159
  PubMedGoogle Scholar
• 53 De Stefano V, Teofili L, Sica S et al.. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia.  Blood. 1995;  86(9) 3535-3541
  PubMedGoogle Scholar
• 54 Cozzolino F, Torcia M, Miliani A et al.. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia.  Am J Med. 1988;  84(2) 240-250
  CrossrefPubMedGoogle Scholar
• 55 Griffin J D, Rambaldi A, Vellenga E, Young D C, Ostapovicz D, Cannistra S A. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors.  Blood. 1987;  70(4) 1218-1221
  PubMedGoogle Scholar
• 56 Bevilacqua M P, Pober J S, Majeau G R, Fiers W, Cotran R S, Gimbrone Jr M A. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.  Proc Natl Acad Sci U S A. 1986;  83(12) 4533-4537
  CrossrefPubMedGoogle Scholar
• 57 Moore K L, Esmon C T, Esmon N L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture.  Blood. 1989;  73(1) 159-165
  PubMedGoogle Scholar
• 58 Nachman R L, Hajjar K A, Silverstein R L, Dinarello C A. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor.  J Exp Med. 1986;  163(6) 1595-1600
  CrossrefPubMedGoogle Scholar
• 59 Degos L, Dombret H, Chomienne C et al.. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.  Blood. 1995;  85(10) 2643-2653
  PubMedGoogle Scholar
• 60 Greeno E W, Bach R R, Moldow C F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity.  Lab Invest. 1996;  75(2) 281-289
  PubMedGoogle Scholar
• 61 Flynn P D, Byrne C D, Baglin T P, Weissberg P L, Bennett M R. Thrombin generation by apoptotic vascular smooth muscle cells.  Blood. 1997;  89(12) 4378-4384
  PubMedGoogle Scholar
• 62 Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus.  Proc Natl Acad Sci U S A. 1996;  93(4) 1624-1629
  CrossrefPubMedGoogle Scholar
• 63 Kwaan H C, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis in cancer.  Semin Thromb Hemost. 2003;  29(3) 283-290
  Article in Thieme ConnectPubMedGoogle Scholar
• 64 Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4).  Blood. 1996;  87(2) 613-617
  PubMedGoogle Scholar
• 65 Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells.  Blood. 1994;  84(9) 3001-3009
  PubMedGoogle Scholar
• 66 Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function.  FASEB J. 1992;  6(8) 2591-2599
  PubMedGoogle Scholar
• 67 Marchetti M, Vignoli A, Bani M R, Balducci D, Barbui T, Falanga A. All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties.  Haematologica. 2003;  88(8) 895-905
  PubMedGoogle Scholar
• 68 Egbring R, Schmidt W, Fuchs G, Havemann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects.  Blood. 1977;  49(2) 219-231
  CrossrefPubMedGoogle Scholar
• 69 Plow E F, Edgington T S. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH.  J Clin Invest. 1975;  56(1) 30-38
  CrossrefPubMedGoogle Scholar
• 70 Nossel H L, Hurlet-Jensen A, Liu C Y, Koehn J A, Canfield R E. Fibrinopeptide release from fibrinogen.  Ann N Y Acad Sci. 1983;  408 269-278
  CrossrefPubMedGoogle Scholar
• 71 Schmidt W, Egbring R, Havemann K. Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors.  Thromb Res. 1975;  6(4) 315-329
  CrossrefPubMedGoogle Scholar
• 72 Brower M S, Harpel P C. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.  J Biol Chem. 1982;  257(16) 9849-9854
  PubMedGoogle Scholar
• 73 Sterrenberg L, van Liempt G J, Nieuwenhuizen W, Hermans J. Anticoagulant properties of purified X-like fragments of human fibrinogen produced by degradation with leukocyte elastase.  Thromb Haemost. 1984;  51(3) 398-402
  PubMedGoogle Scholar
• 74 Dombret H, Scrobohaci M L, Ghorra P et al.. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.  Leukemia. 1993;  7(1) 2-9
  PubMedGoogle Scholar
• 75 Federici A B, Berkowitz S D, Lattuada A, Mannucci P M. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis.  Blood. 1993;  81(3) 720-725
  PubMedGoogle Scholar
• 76 Federici A B, Falanga A, Lattuada A, Di Rocco N, Barbui T, Mannucci P M. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid.  Br J Haematol. 1996;  92(3) 733-739
  CrossrefPubMedGoogle Scholar
• 77 Simak J, Gelderman M P. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers.  Transfus Med Rev. 2006;  20(1) 1-26
  CrossrefPubMedGoogle Scholar
• 78 Horstman L L, Jy W, Jimenez J J, Bidot C, Ahn Y S. New horizons in the analysis of circulating cell-derived microparticles.  Keio J Med. 2004;  53(4) 210-230
  CrossrefPubMedGoogle Scholar
• 79 Tesselaar M E, Romijn F P, Van Der Linden I K, Prins F A, Bertina R M, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.  J Thromb Haemost. 2007;  5(3) 520-527
  CrossrefPubMedGoogle Scholar
• 80 Gralnick H R, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia.  Br J Haematol. 1973;  24(1) 89-99
  CrossrefPubMedGoogle Scholar
• 81 Bennett B, Booth N A, Croll A, Dawson A A. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination.  Br J Haematol. 1989;  71(4) 511-517
  CrossrefPubMedGoogle Scholar
• 82 Tapiovaara H, Alitalo R, Stephens R, Myöhänen H, Ruutu T, Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.  Blood. 1993;  82(3) 914-919
  CrossrefPubMedGoogle Scholar
• 83 Stephens R, Alitalo R, Tapiovaara H, Vaheri A. Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors.  Leuk Res. 1988;  12(5) 419-422
  CrossrefPubMedGoogle Scholar
• 84 Reddy V B, Kowal-Vern A, Hoppensteadt D A et al.. Global and hemostatic markers in acute leukemia.  Am J Clin Pathol. 1990;  94 397-403
  PubMedGoogle Scholar
• 85 Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors.  Blood. 1994;  83(7) 1883-1891
  CrossrefPubMedGoogle Scholar
• 86 Bennett M, Parker A C, Ludlam C A. Platelet and fibrinogen survival in acute promyelocytic leukaemia.  BMJ. 1976;  2(6035) 565
  CrossrefPubMedGoogle Scholar
• 87 Booth N A, Bennett B. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.  Br J Haematol. 1984;  56(4) 545-556
  CrossrefPubMedGoogle Scholar
• 88 Menell J S, Cesarman G M, Jacovina A T, McLaughlin M A, Lev E A, Hajjar K A. Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med. 1999;  340(13) 994-1004
  CrossrefPubMedGoogle Scholar
• 89 Hajjar K A, Jacovina A T, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II.  J Biol Chem. 1994;  269(33) 21191-21197
  PubMedGoogle Scholar
• 90 Hajjar K A, Menell J S. Annexin II: a novel mediator of cell surface plasmin generation.  Ann N Y Acad Sci. 1997;  811 337-349
  CrossrefPubMedGoogle Scholar
• 91 Cesarman G M, Guevara C A, Hajjar K A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation.  J Biol Chem. 1994;  269(33) 21198-21203
  PubMedGoogle Scholar
• 92 Kwaan H C, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin.  J Thromb Haemost. 2004;  2(2) 306-312
  CrossrefPubMedGoogle Scholar
• 93 Lee A Y, Levine M N. The thrombophilic state induced by therapeutic agents in the cancer patient.  Semin Thromb Hemost. 1999;  25(2) 137-145
  Article in Thieme ConnectPubMedGoogle Scholar
• 94 Mitchell L G, Sutor A H, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment.  Semin Thromb Hemost. 1995;  21(4) 390-401
  Article in Thieme ConnectPubMedGoogle Scholar
• 95 Sarris A H, Kempin S, Berman E et al.. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia.  Blood. 1992;  79(5) 1305-1310
  PubMedGoogle Scholar
• 96 Zangari M, Barlogie B, Anaissie E et al.. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.  Br J Haematol. 2004;  126(5) 715-721
  CrossrefPubMedGoogle Scholar
• 97 Anderlini P, Luna M, Kantarjian H M et al.. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.  Leukemia. 1996;  10(4) 600-608
  PubMedGoogle Scholar
• 98 Semeraro N, Colucci M. Changes in the coagulation-fibrinolysis balance of endothelial cells and mononuclear phagocytes: role in disseminated intravascular coagulation associated with infectious diseases.  Int J Clin Lab Res. 1992;  21(3) 214-220
  CrossrefPubMedGoogle Scholar
• 99 ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis.  Crit Care Med. 2000;  28(9, suppl) S9-S11
  CrossrefPubMedGoogle Scholar
• 100 Levi M, Toh C H, Thachil J, Watson H G. British Committee for Standards in Haematology . Guidelines for the diagnosis and management of disseminated intravascular coagulation.  Br J Haematol. 2009;  145(1) 24-33
  CrossrefPubMedGoogle Scholar
• 101 Taylor Jr F B, Toh C H, Hoots W K, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.  Thromb Haemost. 2001;  86(5) 1327-1330
  Article in Thieme ConnectPubMedGoogle Scholar
• 102 Toh C H, Hoots W K. SSC on Disseminated Intravascular Coagulation of the ISTH . The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview.  J Thromb Haemost. 2007;  5(3) 604-606
  CrossrefPubMedGoogle Scholar
• 103 Dixit A, Kannan M, Mahapatra M, Choudhry V P, Saxena R. Roles of protein C, protein S, and antithrombin III in acute leukemia.  Am J Hematol. 2006;  81(3) 171-174
  CrossrefPubMedGoogle Scholar
• 104 Kantarjian H M, Keating M J, Walters R S et al.. Acute promyelocytic leukemia. M.D. Anderson Hospital experience.  Am J Med. 1986;  80 789-797
  CrossrefPubMedGoogle Scholar
• 105 Losada R, Espinosa E, Hernández C, Dorticos E, Hernández P. Thrombocytosis in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment.  Br J Haematol. 1996;  95(4) 704-705
  CrossrefPubMedGoogle Scholar
• 106 Degos L, Dombret H, Chomienne C et al.. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.  Blood. 1995;  85(10) 2643-2653
  PubMedGoogle Scholar
• 107 Bassan R, Battista R, Viero P et al.. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia.  Leukemia. 1995;  9(2) 238-243
  PubMedGoogle Scholar
• 108 British Committee for Standards in Haematology, Blood Transfusion Task Force . Guidelines for the use of platelet transfusions.  Br J Haematol. 2003;  122(1) 10-23
  CrossrefPubMedGoogle Scholar
• 109 Yanada M, Matsushita T, Asou N et al.. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.  Eur J Haematol. 2007;  78(3) 213-219
  CrossrefPubMedGoogle Scholar
• 110 O'shaughnessy D F, Atterbury C, Bolton Maggs P British Committee for Standards in Haematology, Blood Transfusion Task Force et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.  Br J Haematol. 2004;  126(1) 11-28
  CrossrefPubMedGoogle Scholar
• 111 Tallman M S, Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.  Blood. 1992;  79(3) 543-553
  PubMedGoogle Scholar
• 112 Falanga A, Iacoviello L, Evangelista V et al.. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid.  Blood. 1995;  86(3) 1072-1081
  PubMedGoogle Scholar
• 113 Tallman M S, Brenner B, de la Serna J et al.. Meeting report. Acute promyelocytic leukemia-associated coepulopathy; January 21, 2004, London, UK.  Leukemia Res. 2005;  29(3) 347-351
  CrossrefPubMedGoogle Scholar
• 114 Runde V, Aul C, Heyll A, Schneider W, Schneider W. All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia.  Blood. 1992;  79(2) 534-535
  PubMedGoogle Scholar
• 115 Forjaz De Lacenda J, Alves Do Carmo J, Lurdes Guerna M, Geraldes J, Forjaz De Lacerda J M. Multiple thrombosis in acute promyelocytic leukaemia after tretinoin.  Lancet. 1993;  342 114-115
  PubMedGoogle Scholar
• 116 Hashimoto S, Koike T, Tatewaki W et al.. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage.  Leukemia. 1994;  8(7) 1113-1115
  PubMedGoogle Scholar
• 117 Schwartz B S, Williams E C, Conlan M G, Mosher D F. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency.  Ann Intern Med. 1986;  105(6) 873-877
  PubMedGoogle Scholar
• 118 Avvisati G, ten Cate J W, Büller H R, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia.  Lancet. 1989;  2(8655) 122-124
  PubMedGoogle Scholar
• 119 Sugawara T, Okuda M, Yamaguchi Y, Endo K, Yoshinaga K. Successful treatment with tranexamic acid for severe bleeding in acute promyelocytic leukemia.  Acta Haematol. 1992;  87(1–2) 109
  CrossrefPubMedGoogle Scholar
• 120 Warrell Jr R P, de Thé H, Wang Z-Y, Degos L. Acute promyelocytic leukemia.  N Engl J Med. 1993;  329(3) 177-189
  CrossrefPubMedGoogle Scholar
• 121 Franchini M, Manzato F, Salvagno G L, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.  Blood Coagul Fibrinolysis. 2007;  18(7) 589-593
  CrossrefPubMedGoogle Scholar
• 122 Zver S, Andoljsek D, Cernelc P. Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia.  Eur J Haematol. 2004;  72(6) 455-456
  CrossrefPubMedGoogle Scholar
• 123 Alimoghaddam K, Ghavamzadeh A, Jahani M. Use of Novoseven for arsenic trioxide-induced bleeding in PML.  Am J Hematol. 2006;  81(9) 720
  PubMedGoogle Scholar
• 124 Warren B L, Eid A, Singer P KyberSept Trial Study Group et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286(15) 1869-1878
  CrossrefPubMedGoogle Scholar
• 125 Kienast J, Juers M, Wiedermann C J KyberSept investigators et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.  J Thromb Haemost. 2006;  4(1) 90-97
  CrossrefPubMedGoogle Scholar
• 126 Bernard G R, Vincent J L, Laterre P F Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344(10) 699-709
  CrossrefPubMedGoogle Scholar
• 127 Dhainaut J F, Yan S B, Joyce D E et al.. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.  J Thromb Haemost. 2004;  2(11) 1924-1933
  CrossrefPubMedGoogle Scholar
• 128 Bernard G R, Macias W L, Joyce D E, Williams M D, Bailey J, Vincent J L. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.  Crit Care. 2003;  7(2) 155-163
  CrossrefPubMedGoogle Scholar
• 129 Mechtcheriakova D, Wlachos A, Holzmüller H, Binder B R, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1.  Blood. 1999;  93(11) 3811-3823
  PubMedGoogle Scholar
• 130 Kini A R, Peterson L A, Tallman M S, Lingen M W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid.  Blood. 2001;  97(12) 3919-3924
  CrossrefPubMedGoogle Scholar
• 131 Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia.  Best Pract Res Clin Haematol. 2001;  14(1) 153-174
  CrossrefPubMedGoogle Scholar
• 132 Soignet S L, Frankel S R, Douer D et al.. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.  J Clin Oncol. 2001;  19(18) 3852-3860
  PubMedGoogle Scholar

Massimo FranchiniM.D. 

Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine

University Hospital, Via Gramsci, 14, 37124 Parma, Italy

Email: mfranchini@ao.pr.it